Spinocerebellar Ataxia Type 15
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Spinocerebellar Ataxia Type 15

View Main Condition: Movement Disorders

What is the definition of Spinocerebellar Ataxia Type 15?
Spinocerebellar ataxia 15 (SCA15) is a neurological condition characterized by slowly progressive gait and limb ataxia, often in combination with eye movement abnormalities and balance, speech and swallowing difficulties. SCA15 is caused by genetic changes in the ITPR1 gene. It is inherited in an autosomal dominant manner. Diagnosis is based on clinical history, physical examination, molecular genetic testing, and exclusion of other similar diseases.
What are the alternative names for Spinocerebellar Ataxia Type 15?
  • Spinocerebellar ataxia 15
  • SCA15
  • SCA16 (formerly)
  • Spinocerebellar ataxia 16 (formerly)
  • Spinocerebellar ataxia type 15
Who are the top Spinocerebellar Ataxia Type 15 Local Doctors?
Distinguished in Spinocerebellar Ataxia Type 15
Family Medicine
Distinguished in Spinocerebellar Ataxia Type 15
Family Medicine

William M Handy, MD PC

389 Falls Dr NW, 
Abingdon, VA 
Languages Spoken:
English

. Dr. Handy is rated as a Distinguished provider by MediFind in the treatment of Spinocerebellar Ataxia Type 15. His top areas of expertise are Spinocerebellar Ataxia Type 10, Spinocerebellar Ataxia Type 20, Spinocerebellar Ataxia Type 2, and Spinocerebellar Ataxia Type 15.

Arvo Kanna
Experienced in Spinocerebellar Ataxia Type 15
Neurology
Experienced in Spinocerebellar Ataxia Type 15
Neurology

Ballad Health Medical Associates Neurology

1406 Tusculum Boulevard, Suite 1200, 
Greeneville, TN 
Languages Spoken:
English
Offers Telehealth

Arvo Kanna, MD, became a neurologist because he was deeply fascinated by the complexities of the human brain. “My job is like piecing together a puzzle, where I use a patient’s medical history along with examination and tests to find an accurate diagnosis.” Dr. Kanna believes that a strong patient-physician relationship is one of the most important tools a doctor can have. “Creating a personal connection is essential,” he says. “It lets the patient know that you genuinely care.”. Dr. Kanna is rated as an Experienced provider by MediFind in the treatment of Spinocerebellar Ataxia Type 15. His top areas of expertise are Autosomal Dominant Partial Epilepsy with Auditory Features, Epilepsy Juvenile Absence, Absence Seizure, and Memory Loss.

 
 
 
 
Learn about our expert tiers
Learn More
George (. Wilmot
Distinguished in Spinocerebellar Ataxia Type 15
Otolaryngology
Distinguished in Spinocerebellar Ataxia Type 15
Otolaryngology

Emory University Hospital Midtown Campus

550 Peachtree Street Northeast, MedicalOfficeTower, 
Atlanta, GA 
Languages Spoken:
English
Offers Telehealth

George Wilmot is an Otolaryngologist in Atlanta, Georgia. Dr. Wilmot is rated as a Distinguished provider by MediFind in the treatment of Spinocerebellar Ataxia Type 15. His top areas of expertise are Spinocerebellar Ataxia Type 12, Cataract Ataxia Deafness, Spinocerebellar Ataxia Type 4, and Spinocerebellar Ataxia Type 20.

What are the latest Spinocerebellar Ataxia Type 15 Clinical Trials?
Coordination of Rare Diseases at Sanford

Summary: CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures for rare diseases. The CoRDS team works with patient advocacy groups, in...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

What are the Latest Advances for Spinocerebellar Ataxia Type 15?
Rare Spinocerebellar Ataxia Types in Canada: A Case Series and Review of the Literature.
Tired of the same old research?
Check Latest Advances
ITPR1: The missing gene in miosis-ataxia syndrome?